laminin, and cell cohesion [84]. Due to its complex components, the ECM plays a crucial role in determining cell phenotypes in cancer tissues. Abnormal changes in ECM degradation and remodelling are commonly observed in tumour tissues, making it an topic of interest for constructing tumour organoi...
3A), EMT progression (Fig. 3B), and migratory/invasive abilities (Fig. 3C, D) in A549 cells were all significantly reversed. To validate the clinical significance of Snail in patients with lung cancer, a cohort of 426 lung cancer cases from the The Cancer Genome Atlas (TCGA) was analyzed...
28 These results support the hypothesis that pyroptotic molecules are involved in lung cancer development and progression. Effects of pyroptosis on inhibiting lung cancer growth Pyroptosis components, including GSDMD and GSDME, also participated in inhibiting growth of lung cancer cells. There is a ...
FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based che- motherapy. Oncologist 21: 634-642, 2016.Kazandjian, D.; Suzman, D.L.; Blumenthal, G.; Mushti, S.; He, K.; Libeg, M.; Keegan, P.; Pazdur,...
Maiga, A. W.et al.Timeliness of care and lung cancer tumor-stage progression: how long can we wait?.Ann. Thorac. Surg.104(6), 1791–1797 (2017). ArticleGoogle Scholar Lo, D. S.et al.Time to treat: a system redesign focusing on decreasing the time from suspicion of lung cancer to...
Lung cancer is a heterogeneous disease consisting of multiple histological subtypes each driven by unique genetic alterations. Despite the development of targeted therapies that inhibit the oncogenic mutations driving a subset of lung cancer cases, there
Cytokines are playing a key role in the inflammatory tumor microenvironment that is closely associated with cancer progression. They transmit information between cells, facilitate the recruitment of immune cells into the tumor microenvironment and also affect the expression of immune checkpoint receptors and...
This lesson describes the stages and survival rates of non-small cell lung cancer. All cancers are unique, and these figures should be treated as...
Subsequently, a myriad of other studies has demonstrated its key role in lung tumor burden progression as well as chemoresistance, as described below. Non-small cell lung cancer (NSCLC) NSCLC is the most common histologically defined subtype of lung cancer, accounting for 85–90% of all lung ...
Figure 1. Timeline of therapeutic development of immune checkpoint inhibitors in extensive disease (ED) small cell lung cancer (SCLC). CT, chemotherapy; tTMB, tissue tumor mutational burden [∗this is an agnostic approval in all tumors with high tTMB (≥10 mutations per megabase, mut/Mb) bas...